Ascendis Pharma A/S
ASND
274 hedge funds and large institutions have $14.3B invested in Ascendis Pharma A/S in 2026 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 109 increasing their positions, 106 reducing their positions, and 59 closing their positions.
477% more call options, than puts
Call options by funds: $341M | Put options by funds: $59M
33% more funds holding in top 10
Funds holding in top 10: 12 → 16 (+4)
4% more capital invested
Capital invested by funds: $13.8B → $14.3B (+$539M)
3% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 106
3.89% less ownership
Funds ownership: 104.43% → 100.54% (-3.9%)
9% less funds holding
Funds holding: 302 → 274 (-28)
42% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 59
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$1.01B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$202M |
| 3 |
PA
Perceptive Advisors
New York
|
+$101M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$63M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$44.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$866M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$248M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$116M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$99.3M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$83.4M |
ASND Hedge Fund Activity: Q1 2026 in Review
274 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2026, worth a combined $14.3B — up 3.9% from $13.8B a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of ASND and 34 opened new positions — a net loss of 25 holders — while 106 trimmed existing stakes and 109 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $1.01B. The largest seller was Janus Henderson Group, exiting entirely with an estimated $866M sold.
- 274 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2026, down from 302 in Q4 2025.
- Funds reported $14.3B of Ascendis Pharma A/S stock for Q1 2026, up 3.9% quarter-over-quarter.
- 34 funds opened new Ascendis Pharma A/S positions in Q1 2026 and 59 closed out, a net change of -25 holders.
- The largest Ascendis Pharma A/S buyer in Q1 2026 was T. Rowe Price Investment Management, an estimated $1.01B added.
- The largest Ascendis Pharma A/S seller in Q1 2026 was Janus Henderson Group, an estimated $866M sold.
Based on aggregated 13F filings for Q1 2026.